GlassScriptPhysician profile
Sana Ali
NPI 1841819349
$2,907.96
in general payments reported to CMS, 2019-2025
24 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $495 · 2024: $1,182 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.98 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $557.57 | 2024-2025 | |
| Abbvie INC. | $344.88 | 2023-2025 | Venclexta |
| Alexion Pharmaceuticals, INC. | $237.00 | 2023-2025 | Ultomiris |
| Genzyme Corporation | $203.72 | 2023-2025 | |
| Incyte Corporation | $200.20 | 2023-2025 | Monjuvi, Jakafi, Zynyz |
| Janssen Biotech, INC. | $182.04 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Emd Serono, INC. | $159.89 | 2023-2024 | Bavencio |
| Celgene Corporation | $138.29 | 2023-2024 | Reblozyl |
| Merck Sharp & Dohme LLC | $133.09 | 2023-2025 | Keytruda, Keytruda Qlex, Prevymis |
| Daiichi Sankyo INC. | $104.97 | 2023-2025 | Enhertu, Vanflyta |
| Pfizer INC. | $81.69 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $72.77 | 2024 | |
| Gilead Sciences, INC. | $61.70 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $54.32 | 2024-2025 | Xpovio |
| Genentech USA, INC. | $51.20 | 2024 | Phesgo, Itovebi, Herceptin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.87 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.72 | 2024-2025 | Enhertu, Lynparza |
| Agios Pharmaceuticals, INC. | $47.44 | 2025 | Pyrukynd |
| Blueprint Medicines Corporation | $42.82 | 2025 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $31.67 | 2025 | |
| Puma Biotechnology, INC. | $29.89 | 2024 | |
| Kyowa Kirin, INC. | $29.06 | 2024 | Poteligeo |
| Deciphera Pharmaceuticals INC. | $22.26 | 2025 | Qinlock, Tgct |
| Coherus Oncology, INC. | $21.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sana Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.